Navigation Links
PTV Interview Exclusive: Revolutionary GSK and J&J Participation in New Index Ventures Fund
Date:3/21/2012

OXFORD, England, March 21, 2012 /PRNewswire/ --

Fintan Walton talks exclusively to Johnson & Johnson (J&J) and GlaxoSmithKline (GSK) about their participation in Index Ventures' latest fund announced today at BIO-Europe Spring in Amsterdam. This €150m fund includes investments from several of Index's largest existing limited partners and two companies, GSK and the venture capital affiliate of the Janssen pharmaceutical companies of J&J (Janssen).

Francesco De Rubertis of Index Ventures, Dr Moncef Slaoui, Chairman of R&D at GSK and Dr Paul Stoffels, Worldwide Chairman of Johnson & Johnson Pharmaceuticals describe how the two global pharmaceutical companies will share their expertise by participating in the scientific advisory board (SAB) of the fund.

Index will maintain full decision making rights to the portfolio companies and the fund rules and procedures will follow previous Index Ventures funds. This unique pharma/venture partnership model is intended to stimulate promising, early-stage R&D innovation.

Note to Editors

If you wish to write an article, please contact us for any further information you require.

About PharmaVentures

PharmaVentures (http://www.pharmaventures.com) is an international healthcare advisory group providing leadership in all aspects of deals and alliances, from strategy formulations to implementation. The company occupies a special position in the global marketplace because of our track record of successful outcomes, resulting from our unique insight into the world of deal making, our internationally recognised analytical and valuation capabilities, our own proprietary deal making database PharmaDeals® (http://www.pharmadeals.net), containing over 43,000 deal records, and our extensive business relationship network and our outstanding success in M&A transactions.

Our Services Cover:

  • Valuation (for licensing, acquisitions, divestments, fund raising & expert testimonies)
  • Licensing (In and Out licensing)
  • M&A (Companies & Assets)
  • Strategy (commercialisation, deal strategy, due diligence, market entry)
  • Expert Testimony (Patent Infringement, Deal Disagreements, Taxation, Determining Damages)

PharmaVentures' subsidiary, PharmaTelevision®, is the world's first dedicated online pharmaceutical television channel (http://www.pharmatelevision.com).

Now in its 20th year, PharmaVentures is based in Oxford, UK, and employs over 30 people.

PharmaDeals®, PharmaTelevision® and PharmaVentures® are registered Trade Marks of PharmaVentures Ltd.

For further information, contact:
Fintan Walton
CEO
PharmaVentures
+44 1865 332700
enquiries@pharmaventures.com


'/>"/>
SOURCE PharmaVentures
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. The Wall Street Transcript Interviews AMDL, Inc. CEO & President Gary Dreher for Fall Healthcare Issue
2. [video] Wall St. Networks 3-Minute Press Show Features Executive Interviews and Highlights Recent Press for the Following: IMMU, KYUS
3. CFO of China Yingxia Emphasizes Growth in Organic and Health Food Segment in Interview by The Wall Street Transcript
4. [video] Wall St. Networks 3-Minute Press Show Features Executive Interviews and Highlights Recent Press for the Following: GTHR, BHRT, AGO
5. China Sky One Medical, Inc. Interviewed in The China Perspective
6. Jatropha World 2009 Advance Access: Surprisingly Candid Interview Series Examines Biofuel Predictions Compared to Fossil Fuels
7. Jatropha World 2009 Advance Access: Surprisingly Candid Interview Series Examines Biofuel Predictions Compared to Fossil Fuels
8. In Analyst Interview, Cord Blood America Says Stem Cells Now Front and Center for Researchers and Investors
9. In Analyst Interview, Cord Blood America Provides Details of Special Shareholder Meeting
10. Web-based Audio Interviews Keep Environment of Care Managers Up-to-Date on Key EC Compliance Issues
11. HIKMA - 2008 Preliminary Results Interview With CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a ... eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research ... by providing practical tips, tools, and strategies for clinical researchers. , “The landscape ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)... June 23, 2016 A person commits a crime, ... scene to track the criminal down. An outbreak ... and Drug Administration (FDA) uses DNA evidence to track down ... Sound far-fetched? It,s not. The FDA has increasingly used ... investigations of foodborne illnesses. Put as simply as possible, whole ...
(Date:6/23/2016)... ... 23, 2016 , ... Charm Sciences, Inc. is pleased to ... AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of the ... Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably ...
Breaking Biology Technology:
(Date:6/9/2016)... an innovation leader in attendance control systems is proud to announce the introduction of ... make sure the right employees are actually signing in, and to even control the ... ... ... ...
(Date:6/7/2016)... 7, 2016  Syngrafii Inc. and San Antonio ... that includes integrating Syngrafii,s patented LongPen™ eSignature "Wet" ... collaboration will result in greater convenience for SACU ... while maintaining existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/2/2016)... 2016 The Department of Transport Management ... 44 million US Dollar project, for the , ... Personalization, Enrolment, and IT Infrastructure , to ... and implementation of Identity Management Solutions. Numerous renowned international vendors ... Decatur was selected for the most compliant and ...
Breaking Biology News(10 mins):